ArticleBMJ global health2025
Evaluating geographic accessibility to COVID-19 vaccination across 54 countries/regions.
Article in BMJ global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Article
- The KPROCS Study: A Real-World and Research Resource to Investigate Multilevel Determinants of Ovarian Cancer Treatment and Survival.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Institutional factors influencing vaccine access in Canada: a scoping review.BMC public health · 2026Article
- Geospatial analysis of COVID-19 vaccine access in Kenya: the interplay of travel time, perceived availability, and vaccine uptake.Journal of global health · 2026Article
- Equitable access to the COVID-19 vaccines in Africa (ECOVA) findings from a qualitative enquiry in Zimbabwe.Frontiers in health services · 2026Article
- Examining healthcare inequality for non-communicable diseases in Malawi: a hierarchical geospatial modelling approach.BMJ health & care informatics · 2025Article
- Accessibility of Ontario pharmacies offering COVID-19 vaccination by rurality, community material deprivation, and ethnic concentration: a repeated cross-sectional geospatial analysis.BMC public health · 2025Article
- Using black knowledges to recognise and address barriers to COVID-19 vaccination in Malawi.BMC public health · 2025Article
- Identifying Areas with Low Access to the COVID-19 Vaccine: A New Objective Framework Incorporating Mobility Data.Healthcare (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe COVID-19 pandemic has revealed significant disparities in global vaccine accessibility, particularly affecting low and middle-income countries (LMICs). However, current research on COVID-19 vaccine accessibility primarily focuses on individual countries or high-income countries (HIC). We aimed to evaluate geographic accessibility to COVID-19 vaccination on a multicountry scale, covering comparisons across LMICs and HICs. Additionally, we explored the potential economic factors related to accessibility and their impacts on health outcomes.
methodsWe collected population data at a 1 km resolution and geocoded all vaccination sites across the selected countries/regions. Four measures were used to evaluate vaccine accessibility from different perspectives: population coverage with varying travel time thresholds, driving time to vaccination sites, the number of sites within a 30-min threshold and a geographic accessibility index using enhanced two-step floating catchment area method. Finally, we explored the relationships between geographic accessibility and several factors: gross domestic product per capita, vaccination uptake and mortality.
findingsWe found substantial disparities in vaccine accessibility across the selected countries/regions. In 24.07% of these countries/regions, over 95% of the population can access the nearest vaccination services within 15 min. In contrast, in countries/regions such as Manitoba (Canada), Zimbabwe and Bhutan, less than 30% of the population can reach these sites within 60 min. Underserved areas, termed 'vaccine deserts', were identified in both HICs and LMICs. We found that countries/regions with higher vaccine accessibility tend to achieve higher vaccination rates, whereas those with lower vaccine accessibility are likely to experience substantial increases in COVID-19 mortality rates.
conclusionLMICs require enhanced attention to improve geographic accessibility to vaccination. Additionally, there are internal disparities in accessibility within both HICs and LMICs. National public health officials and global health initiatives are suggested to prioritize 'vaccine deserts' and to ensure equitable vaccine access in future pandemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.